Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

Nicholas Company Inc. Acquires New Position in Amgen Inc. $AMGN

📈 Nicholas Company Inc. increased its Amgen stake by acquiring 16,415 shares valued at $5.37 million in the fourth quarter.

🏢 Robeco Institutional Asset Management B.V. grew its Amgen holdings by 10% to own 481,453 shares worth $157.58 million.

📊 Sequoia Financial Advisors LLC increased its position by 2.3%, now holding 160,646 shares valued at $45.33 million.

💰 Curtis Advisory Group LLC established a new position in Amgen worth approximately $1.67 million during the fourth quarter.

📈 Global Wealth Management Investment Advisory Inc. significantly expanded its stake by 56.2% to own shares totaling $3.68 million.

🔄 Jones Financial Companies Lllp grew its holdings by 18.2%, adding 6,115 shares for a total value of $10.89 million.

🏛️ Institutional investors collectively control 76.50% of Amgen's outstanding stock as of the latest filings.

📉 SVP Nancy A. Grygiel sold 1,237 shares worth $400,454 on May 4th, reducing her direct ownership by 15%.

💹 Shares of Amgen opened at $331.70 and are currently trading with a market capitalization of $179.01 billion.

📉 The stock trades at a P/E ratio of 23.08 with a beta of 0.44, indicating lower volatility compared to the broader market.

🏆 Amgen reported Q1 earnings of $5.15 per share, surpassing analyst estimates of $4.77 by $0.38.

💰 The company generated revenue of $8.62 billion for the quarter, up 5.8% from the prior year period.

🎯 Amgen provided FY 2026 EPS guidance ranging between $21.70 and $23.10 for the current fiscal year.

💵 A quarterly dividend of $2.52 per share will be paid to investors of record on May 15th, with an ex-dividend date of May 15th.

🔄 The total annualized dividend is projected at $10.08 per share, resulting in a current yield of 3.0%.

Bullish Signals
  • Amgen reported $5.15 earnings per share for the quarter, significantly beating analysts' consensus estimates of $4.77 by $0.38.
  • The company generated revenue of $8.62 billion, exceeding analyst expectations of $8.58 billion, marking a 5.8% year-over-year growth.
  • Amgen achieved a robust net margin of 20.96% and an impressive return on equity of 137.41%.
  • Multiple institutional investors increased their stakes, with Nicholas Company Inc., Robeco Institutional Asset Management B.V., and Global Wealth Management Investment Advisory Inc. growing or initiating positions in the fourth quarter.
  • The company has established a strong future outlook by setting full-year 2026 guidance for earnings per share between $21.70 and $23.10, while analysts anticipate $22.36.
  • Amgen initiated a quarterly dividend of $2.52 per share to be paid on June 5th, offering an attractive annualized yield of 3.0%.
  • With a market capitalization of $179.01 billion and a P/E/G ratio of 3.33, the stock presents favorable valuation metrics relative to growth expectations.
Risk Factors
  • Amgen Inc (NASDAQ: AMGN) shows a debt-to-equity ratio of 5.65, indicating significant leverage that could amplify losses in adverse market conditions.
  • The stock price opened at $321.70 on Monday, while trading well below its 50-day moving average of $355.12, suggesting bearish short-term sentiment.
  • SVP Nancy A. Grygiel sold 1,237 shares representing a 15.00% decrease in her direct ownership, signaling potential insider concern about the stock's near-term prospects.
  • With an annualized dividend of $10.08 per share and a payout ratio of 70.15%, Amgen has limited flexibility to return capital during periods of financial stress.
  • Analyst expectations for FY 2026 EPS stand at $22.36, yet the company's own guidance is lower (21.700-23.100), suggesting management sees a challenging outlook compared to market consensus.
Full Analysis
Amgen Inc. (NASDAQ:AMGN) saw increased interest from institutional investors following the fourth quarter filings, with Nicholas Company Inc. acquiring a new position valued at approximately $5.373 million for 16,415 shares. Other major institutional changes include Robeco Institutional Asset Management B.V., which increased its stake by 10% to own 481,453 shares worth roughly $157.58 million, and Global Wealth Management Investment Advisory Inc., which significantly grew its holdings by 56.2% in the third quarter. Additionally, Curtis Advisory Group LLC and Sequoia Financial Advisors LLC established or increased their respective positions during Q3 and Q4, while Jones Financial Companies Lllp also expanded its stake by 18.2%. As of the reporting period, institutional investors collectively hold 76.50% of Amgen’s outstanding stock. Corporate insider activity saw SVP Nancy A. Grygiel sell 1,237 shares on Monday, May 4th, at an average price of $323.73 per share, resulting in a total transaction value of $400,454.01 and a 15% reduction in her personal ownership. Following the sale, Grygiel directly held 7,009 shares valued at approximately $2.269 million. Overall, corporate insiders currently own 0.85% of the company’s stock. The SEC document detailing these transactions is publicly available. Fundamentally, Amgen reported strong quarterly earnings for the period ending April 30th, posting earnings per share of $5.15 which exceeded analysts’ consensus estimates of $4.77 by $0.38. The company generated revenue of $8.62 billion, surpassing the forecasted $8.58 billion, with a net margin of 20.96% and an impressive return on equity of 137.41%. Year-over-year revenue grew by 5.8%, and analysts currently anticipate full-year earnings per share of $22.36 for the fiscal year. Amgen recently announced a quarterly dividend to be paid on June 5th to shareholders of record as of May 15th, set at $2.52 per share. This translates to an annualized dividend of $10.08 and a yield of 3.0%. The company has maintained positive market metrics with a market capitalization of $179.01 billion and a P/E ratio of 23.08. Stock prices are trading near the middle of its yearly range, opening at $331.70, compared to a twelve-month low of $261.43 and high of $391.29, with significant moving averages hovering in the $355 and $342 ranges.